E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
unresectable stage III NSCLC (Non–small-cell lung cancer) |
|
E.1.1.1 | Medical condition in easily understood language |
unresectable stage III NSCLC (Non–small-cell lung cancer) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029519 |
E.1.2 | Term | Non-small cell lung cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029520 |
E.1.2 | Term | Non-small cell lung cancer stage IIIA |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029521 |
E.1.2 | Term | Non-small cell lung cancer stage IIIB |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025052 |
E.1.2 | Term | Lung cancer non-small cell stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025054 |
E.1.2 | Term | Lung cancer non-small cell stage IIIB |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025053 |
E.1.2 | Term | Lung cancer non-small cell stage IIIA |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of either conventionally fractionated (CON-group) or hypofractionated (HYPO-group) thoracic radiotherapy in combination with durvalumab.
Primary efficacy objective To investigate the efficacies of either mode of fractionation of radiotherapy in combination with durvalumab with respect to the response rates in patients with unresectable stage III NSCLC, who are not suitable for chemotherapy.
|
|
E.2.2 | Secondary objectives of the trial |
To determine further parameters for efficacy, safety, and quality of life in both treatment arms.
Exploratory objectives Vulnerability assessment is based on the G8-screening questionnaire. We choose G8 as our screening tool because it is a simple and fast screening tool with great potential for identifying patients with a geriatric risk profile and it has a strong prognostic value for functional decline and OS in an older population with cancer (Kenis et al., 2014). Collection of tumor tissue, blood and stool samples for separate biomarker research project. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Fully-informed written consent and locally required authorization (European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations. 2. Age ≥ 18 years. 3. Histologically documented diagnosis of unresectable stage III NSCLC. 4. Non-feasibility of sequential chemo-/radiotherapy as determined by the site’s multi-disciplinary tumor board; If there is no tumor board, then this decision will be made by the investigator in consultation with a radiation oncologist, if the investigator is not a radiation oncologist; or by the investigator in consultation with an oncologist, if the investigator is not an oncologist. 5. Fulfills at least one of the following criteria: • Performance status (PS) 2 (ECOG scale) • ECOG 1 and CCI ≥ 1 • Age ≥ 70 years 6. Must have a life expectancy of at least 12 weeks. 7. FEV1 ≥ 40% (Best/Soll) 8. DLCO or DLCO/VA (Hb-corrected, if available) ≥ 40% (Best/Soll) 9. FVC or VC ≥ 70% (Best/Soll) 10. At least one measurable site of disease as defined by RECIST 1.1 criteria. 11. Adequate bone marrow and renal function including the following: o Hemoglobin ≥ 9.0 g/dL; o absolute neutrophil count ≥ 1.0 x 10^9/L; o platelets ≥75x 10^9/L; o Calculated creatinine clearance ≥30 mL/min as determined by the Cockcroft-Gault equation 12. Adequate hepatic function (with stenting for any obstruction, if required) including the following: o Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); o AST (SGOT) / ALT (SGPT) ≤ 2.5x institutional ULN 13. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial. 14. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: o Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). o Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). 15. The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations. |
|
E.4 | Principal exclusion criteria |
1. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study. 2. Participation in another clinical study with an investigational product within 21 days prior to the first dose of the study treatment. 3. Prior immunotherapy or use of other investigational agents, including anti-PD-1, anti-PD-L1, including durvalumab, anti-PD-L2, or anti-CTLA-4 antibody, therapeutic cancer vaccines. 4. History or current radiology suggestive of interstitial lung disease. 5. Oxygen-dependent medical condition. 6. Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (e.g., hormone replacement therapy) is acceptable. 7. Prior thoracic radiotherapy within the past 5 years before the first dose of study drug. 8. Major surgery within 4 weeks prior to enrollment into the study; patients must have recovered from effects of any major surgery. 9. Active or prior documented autoimmune or inflammatory disorders (except inflammatory bowel disease [e.g. ulcerative colitis or Crohn's disease]; (including diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis, or Wegener’s syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion: Patients with vitiligo or alopecia, Patients with hypothyroidism (e.g., following Hashimoto’s disease) stable on hormone replacement, Any chronic skin condition that does not require systemic therapy, Patients without active disease in the last 5 years may be included but only after consultation with the study physician 10. Active, uncontrolled inflammatory bowel disease [e.g. ulcerative colitis or Crohn's disease]. Patients in stable remission for more than 1 year may be included. 11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, interstitial lung disease, gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent. 12. History of another primary malignancy except for: Malignancy treated with curative intent and with no known active disease ≥ 3 years before the first dose of IP and of low potential risk for recurrence; Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; Adequately treated carcinoma in situ without evidence of disease 13. History of leptomeningeal carcinomatosis 14. History of active primary immunodeficiency 15. History of allogenic organ or tissue transplantation. 16. Clinical diagnosis of active tuberculosis. 17. Positive testing for HBV sAg or HCV RNA indicating acute or chronic infection. Patients with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. 18. Positive testing for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). 19. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion: o Intranasal, inhaled, topical steroids, or local steroid injections o Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent o Steroids as premedication for hypersensitivity reactions 20. Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IMP and up to 30 days after the last dose of IMP. 21. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab monotherapy. 22. Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the product. 23. Any co-existing medical condition that in the investigator’s judgement will substantially increase the risk associated with the patient’s participation in the study. 24. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities. 25. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Toxicity, defined by the occurence of treatment-related pneumonitis grade ≥3.
Primary efficacy endpoint: Objective response according to RECIST 1.1 criteria
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
A safety interim assessment based on the primary safety endpoint, occurrence of a grade 3/4 pneumonitis, is conducted after 18 patients have been enrolled into the HYPO-group.
An interim efficacy analysis based on the objective response rate (ORR) will be conducted after n=18 response-evaluable patients in each arm. The response-evaluable population is defined as all enrolled patients who started TRT, received at least one dose of durvalumab and provided at least one post-baseline response assessment. The response-evaluable population will be used as the primary population for the analysis of the primary efficacy endpoint ORR.
Final analysis will be done after LPLV / at end of trial.
|
|
E.5.2 | Secondary end point(s) |
• Occurence of treatment-related AEs and SAEs according to CTCAE V5.0 • Abnormal values of laboratory parameters • PFS according to RECIST 1.1 • Duration of Clinical Benefit (Duration of CR, PR, SD) according to RECIST 1.1 • MFS • OS • QoL (FACT-L) • Descriptive sub-group analyses of efficacy in relation to PD-L1 expression levels (<°1% vs ≥°1%)
Exploratory endpoints: • Vulnerability assessment based on the G8-screening questionnaire and its association to survival and outcome • Collection of blood- and stool based biomarker samples for future research
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Regarding the safety parameters: A safety interim assessment is conducted after 18 patients have been enrolled to the HYPO-group.
Final analysis will be done after LPLV / at end of trial. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |